Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Respiratory Investigation|December 3, 2014
Recent evidence, advances, and current practices in surgical treatment of lung cancerKenichi Suda, Katsuaki Sato, Hiroshi Mizuuchi, et al.
Lung Cancer (Amsterdam, Netherlands)|February 19, 2017
Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cellsYuichi Sesumi, Kenichi Suda, Hiroshi Mizuuchi, et al.
Lung Cancer (Amsterdam, Netherlands)|February 25, 2021
Dose-dependence in acquisition of drug tolerant phenotype and high RYK expression as a mechanism of osimertinib tolerance in lung cancerShuta Ohara, Kenichi Suda, Toshio Fujino, et al.
Lung Cancer (Amsterdam, Netherlands)|December 12, 2018
Effects of secondary EGFR mutations on resistance against upfront osimertinib in cells with EGFR-activating mutations in vitroMasaya Nishino, Kenichi Suda, Yoshihisa Kobayashi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 7, 2019
Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In VitroToshio Fujino, Yoshihisa Kobayashi, Kenichi Suda, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 8, 2018
EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to DacomitinibYoshihisa Kobayashi, Toshio Fujino, Masaya Nishino, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2018
Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve LesionsKenichi Suda, Jihye Kim, Isao Murakami, et al.
Lung Cancer (Amsterdam, Netherlands)|November 6, 2021
In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trialAkira Hamada, Kenichi Suda, Takamasa Koga, et al.
Pageof 4